| 2.21 -0.73 (-24.83%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.17 |
1-year : | 3.71 |
| Resists | First : | 2.72 |
Second : | 3.18 |
| Pivot price | 2.27 |
|||
| Supports | First : | 1.98 |
Second : | 1.64 |
| MAs | MA(5) : | 2.57 |
MA(20) : | 2.29 |
| MA(100) : | 2.25 |
MA(250) : | 6.66 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 63.3 |
D(3) : | 69 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 30.39 | Low : | 1.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AEMD ] has closed above bottom band by 44.6%. Bollinger Bands are 94.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.76 - 2.78 | 2.78 - 2.79 |
| Low: | 2.09 - 2.11 | 2.11 - 2.12 |
| Close: | 2.19 - 2.21 | 2.21 - 2.23 |
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Wed, 27 May 2026
AEMD Stock Pops As Hemopurifier Draws Ebola Outbreak Focus - StocksToTrade
Wed, 27 May 2026
Medical Tech Stock Aethlon Medical (Nasdaq: AEMD) Jumps Amid Escalating Ebola Crisis - Investorideas.com
Wed, 27 May 2026
AEMD Stock Jumps As Hemopurifier Spotlight Returns On Ebola - timothysykes.com
Thu, 21 May 2026
Aethlon Medical (AEMD) Monitors Ebola Outbreak for Hemopurifier® Applications - GuruFocus
Thu, 21 May 2026
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness - Yahoo Finance
Fri, 15 May 2026
Armistice Capital (AEMD) files Schedule 13G/A disclosing 4.99% stake - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 14 (K) |
| EPS | -48.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -62.9 % |
| Return on Equity (ttm) | -208.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|